Studies in cancer mouse models revealed that IL-33 from the tumor microenvironment initiates ST2 signaling in Tregs, as well as positively regulating ST2 expression, resulting in enhanced suppressive function, greater AREG production, and increased tumor number and size (156, 157). This evidence concerns the gene IL1RL1 and neoplasm.